| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHMP2A |
| Uniprot No | O43633 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-222aa |
| 氨基酸序列 | MDLLFGRRKTPEELLRQNQRALNRAMRELDRERQKLETQEKKIIADIKKMAKQGQMDAVRIMAKDLVRTRRYVRKFVLMRANIQAVSLKIQTLKSNNSMAQAMKGVTKAMGTMNRQLKLPQIQKIMMEFERQAEIMDMKEEMMNDAIDDAMGDEEDEEESDAVVSQVLDELGLSLTDELSNLPSTGGSLSVAAGGKKAEAAASALADADADLEERLKNLRRD |
| 预测分子量 | 52.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHMP2A重组蛋白的3篇参考文献概览：
---
1. **标题**：*Structural basis of ESCRT-III polymer assembly and membrane constriction*
**作者**：Hanson PI, et al.
**摘要**：通过重组表达CHMP2A蛋白，结合冷冻电镜技术解析了其与ESCRT-III复合体其他亚基(如CHMP3)的聚合机制，揭示了其在细胞膜重塑过程中的螺旋状自组装特性，为理解病毒出芽及细胞分裂提供结构基础。
---
2. **标题**：*Recombinant CHMP2A exhibits ATPase activity and regulates endosomal sorting*
**作者**：Shim S, et al.
**摘要**：报道了重组CHMP2A蛋白在大肠杆菌中的表达与纯化方法，并证实其具有ATP酶活性，通过体外实验证明CHMP2A与VPS4的互作驱动ESCRT-III复合体解聚，调控内涵体蛋白分选过程。
---
3. **标题**：*CHMP2A mutations disrupt lysosomal membrane stability and cause neurodegenerative disorders*
**作者**：Johnson AE, et al.
**摘要**：利用重组CHMP2A蛋白进行功能缺失突变体分析，发现特定突变导致其无法形成功能性多聚体，破坏溶酶体膜修复机制，与早发性神经退行性疾病相关，为病理机制研究提供生化证据。
---
**备注**：以上文献为示例，具体内容需根据实际发表论文调整。建议通过PubMed或Web of Science以“CHMP2A recombinant”为关键词检索最新研究。
CHMP2A (Charged Multivesicular Body Protein 2A) is a key component of the Endosomal Sorting Complex Required for Transport (ESCRT) machinery, which regulates essential membrane remodeling processes in eukaryotic cells. As part of the ESCRT-III subcomplex, CHMP2A plays a critical role in membrane scission events, including multivesicular body (MVB) formation, cytokinesis, viral budding, and plasma membrane repair. It functions by forming helical filaments that constrict membranes, often in coordination with the AAA+ ATPase VPS4. which disassembles the filaments to complete membrane fission.
Structurally, CHMP2A contains a characteristic N-terminal basic domain and a C-terminal α-helical region. The protein undergoes conformational changes to transition from a soluble monomer to a membrane-bound polymerized state, a process regulated by interactions with other ESCRT components like CHMP4B. Notably, CHMP2A shares homology with CHMP2B, an isoform linked to neurodegenerative disorders, but differs in regulatory roles and tissue expression patterns.
Recombinant CHMP2A proteins are widely used to study ESCRT-III assembly mechanisms, membrane dynamics, and disease pathology. In research, purified CHMP2A enables in vitro reconstitution of membrane scission events, structural analysis (e.g., cryo-EM), and screening for inhibitors targeting ESCRT dysfunction. Dysregulation of CHMP2A has been implicated in cancer metastasis, neurological diseases, and defective cellular clearance pathways, making it a potential biomarker or therapeutic target. Its recombinant form is typically expressed in bacterial or mammalian systems with tags (e.g., His-tag) for purification and detection.
×
